High-Potency Multi-Step Custom Organic Synthesis and API Intermediates
Specialized chemical development suites executing complex 10- to 20-step multi-step organic synthesis, stereoselective cryogenic reactions (-80°C), hazardous organometallic chemistry (organolithiums, Grignard), and niche active pharmaceutical ingredients under cGMP and strict containment.
1 · What it gives
High-Potency Multi-Step Custom Organic Synthesis and API Intermediates represents a critical node in high-value fine chemical and active pharmaceutical ingredient (API) biomanufacturing, overcoming the thermodynamic limits, toxic waste streams, and low stereoselectivity associated with legacy multi-step organometallic synthesis. Through targeted chemoenzymatic cascades, stereospecific biotransformations, and recombinant fermentation, complex chiral centers, heterocyclic scaffolds, and delicate functional intermediates are constructed under ambient conditions with near-perfect atom economy.
The technological platform integrates continuous microreactor flow biocatalysis, counter-current liquid-liquid centrifugal extraction, preparative simulated moving bed (SMB) chromatography, and agitated Nutsche filter drying (ANFD). Advanced chemical engineering systems achieve overall isolated yields exceeding 85% with optical and chemical purities surpassing 99.8%. Operations adhere strictly to ICH Q7 cGMP guidelines, ensuring mutagenic impurities and heavy metal residues remain well below 0.05% thresholds in full compliance with global pharmacopeias.
The key directions of this technology are:
- Chemoenzymatic Route Engineering in High-Potency Multi-Step Custom Organic Synthesis and API Intermediates: Interlocking synthetic organic chemistry with stereospecific biocatalytic steps (ketoreductases, transaminases) to truncate synthetic routes by up to 60%.
- Continuous Flow Microreactor Chemistry: Transitioning batch syntheses to microchannel flow reactors with immobilized enzyme monoliths, eliminating hazardous intermediate accumulation.
- Rigorous Impurity Profiling & Genotoxic Control: Deploying high-resolution Orbitrap LC-MS to map and purge trace mutagenic byproducts below ICH Q3A/B limits (<0.05%).
- Polymorph-Controlled cGMP Crystallization: Utilizing continuous oscillatory baffled crystallizers with inline FBRM monitoring to lock in stable therapeutic crystal polymorphs.
Sectoral value chain#
┌────────────────────────────────────────────────────────┐
│ Tier 1: Chiral Precursor Activation & Sourcing │
│ (Starting materials cGMP assay & pre-activation) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 2: Chemoenzymatic Continuous Flow Reactor │
│ (Immobilized enzyme microchannel with cofactor recycle│
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 3: Counter-Current Centrifugal Extraction │
│ (Multi-stage liquid-liquid organic solvent partition) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 4: Preparative Chiral SMB Chromatography │
│ (Simulated moving bed resolving optical antipodes) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 5: ANFD Controlled Crystallization & Drying │
│ (Enclosed Nutsche filter drying & jet micronization) │
└────────────────────────────────────────────────────────┘
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Starting Material Activation | Synthesis, incoming compendial quality control, and dissolution of pro-chiral key starting materials (KSM). | In: Commercial fine chemicals, solvents, activation reagents. Out: Sterile, analytical-grade pro-chiral feed solution (>98.5% purity). |
| Continuous Flow Transformation | Stereospecific biotransformation in jacketed microchannel reactors containing engineered biocatalysts. | In: Pro-chiral substrate, immobilized enzymes, recycled NADPH. Out: High-conversion reaction stream (>99.0% conversion, ee >99.8%). |
| Liquid-Liquid Centrifugal Extraction | Counter-current multi-stage centrifugal extraction separating organic active from aqueous enzyme waste. | In: Reaction effluent, pharmaceutical ethyl acetate/heptane. Out: Concentrated organic product extract (spent enzymes separated). |
| Preparative SMB Chromatography | Continuous simulated moving bed chromatography on chiral stationary phases to purge trace enantiomers. | In: Organic extract, mobile phase solvents. Out: Chromatographically pure API stream (all impurities <0.10%). |
| Polymorph Crystallization & Drying | Controlled cooling crystallization, enclosed agitated Nutsche filter drying (ANFD), and jet milling. | In: Purified stream, seed crystals, pharmaceutical nitrogen. Out: Compendial-grade micronized cGMP API (>99.8% purity, Form I). |
Cross-cutting technologies of the sector:
- Enclosed Agitated Nutsche Filter Dryers (ANFD): Contained pressure filtration, multi-solvent displacement washing, and vacuum drying in a single cGMP vessel.
- Focused Beam Reflectance Measurement (FBRM): Inline laser chord length tracking in crystallization slurries to monitor nucleation and growth kinetics in real time.
2 · What it replaces 3 · matched by industry
3 · How to implement 4 steps
- 1Stereoselective asymmetric induction reaction designDesigning stereoselective synthetic routes utilizing chiral auxiliaries or transition-metal asymmetric catalysts achieving >99% enantiomeric excess.
- 2Cryogenic large-scale reaction vessel engineeringExecuting multi-hundred liter cryogenic reactions down to -80°C in jacketed Hastelloy reactors with liquid nitrogen cooling coils.
- 3Hazardous reagent and highly reactive chemistry handlingSafe dosing of pyrophoric organolithiums, hydrides, and toxic gases (carbon monoxide, diazomethane) using automated feed systems.
- 4Comprehensive spectroscopic intermediate purity validationValidating chemical structures and chiral purity via high-field NMR (500 MHz), LC-MS, GC-MS, and polarimetry under cGMP quality assurance.
4 · Who delivers
Matched suppliers (matched automatically)
| SyncoZymes (Shanghai) | China | Producer | active |
| Jiangsu Institute of Ecomones Co., Ltd. | China | Research / RTO | active |
| Nature Energy | Denmark | Producer | active |
| PI Industries Ltd | India | Producer | active |
| VIORYL CHEMICAL & AGRICULTURAL INDUSTRY, RESEARCH S.A. | Greece | Research / RTO | active |
| Shandong Bailong Chuangyuan (BLD Bio) | China | Research / RTO | active |
| Bontac Bio-Engineering (Shenzhen) Co., Ltd | China | Research / RTO | active |
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Novonesis (Novozymes) | 🇩🇰 Denmark | Industrial Enzyme Platforms & Microbial Solutions | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
| Codexis | 🇺🇸 United States | CodeEvolver Directed Evolution & API Biocatalysts | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
| BASF | 🇩🇪 Germany | Integrated Chemical & Biocatalytic Synthesis | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
| Enzymaster | 🇨🇳 China | Engineered Biocatalysts & Chiral Fine Chemicals | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
| Lonza | 🇨🇭 Switzerland | Microbial CDMO & Custom Biocatalysis Platforms | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
| Evonik Industries | 🇩🇪 Germany | Fermentation Biosurfactants & Specialty Intermediates | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
5 · Rules & route to market
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
FDA CDER cGMP compliance, Type II Drug Master File (DMF), BARDA critical onshoring#
- FDA 21 CFR Part 210/211 cGMP Compliance: Comprehensive operational validation and quality assurance for active pharmaceutical manufacturing of High-Potency Multi-Step Custom Organic Synthesis and API Intermediates.
- Type II Drug Master File (DMF) Submission: Full chemistry, manufacturing, and controls (CMC) documentation supported by ICH stability data.
- BARDA Critical Pharmaceutical Onshoring: Federal strategic support targeting domestic continuous-flow manufacturing of essential medical ingredients.
European Union
EMA Active Substance Master File (ASMF), EDQM CEP certification, Critical Medicines Alliance#
- EMA & EDQM CEP Certification: Issuance of Certificates of Suitability demonstrating adherence to European Pharmacopoeia (Ph. Eur.) standards.
- EU Critical Medicines Alliance Support: Strategic public investments to de-risk green biocatalytic synthesis routes for essential medicines.
- ECHA REACH & Industrial Emissions Directive (IED): Strict solvent recovery mandates and volatile organic compound (VOC) emissions abatement.
China
14th Five-Year Bioeconomy Strategy, National Medical Products Administration (NMPA) GMP, ChP 2025#
- Green Pharmaceutical Manufacturing Priority: Strategic industrialization of 多步复杂立体手性医药化学中间体与特种高附加值精细化学品定制合成(CRO/CDMO)成套体系 within API hubs across Zhejiang, Jiangsu, and Shandong.
- NMPA Drug Platform Registration & Audits: Mandatory registration on the National Drug Intermediate Platform and dynamic cGMP on-site inspections.
- Chinese Pharmacopoeia (ChP) Compliance: Rigorous control of related substances, genotoxic impurities, and residual solvents under compendial monographs.
6 · Money: tenders & grants
| Grant | Development of cell-free protein synthesis platforms for discovery and/or production of biologicals European Commission · EU | Apr 13, 2027 141 days |
| Grant | Enhancing the competitiveness of organic crop breeding: focus on intercropping adapted varieties European Commission · EU | Sep 22, 2027 303 days |
| Grant | Agriculture and Food Research Initiative Competitive Grants Program Education and Workforce Development National Institute of Food and Agriculture · United States | Dec 31, 2026 38 days |
| Grant | Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the … National Institutes of Health · United States | Aug 18, 2027 268 days |
| Grant | CHIPS Research and Development Office (CRDO) Broad Agency Announcement (BAA) National Institute of Standards and Technology · United States | Sep 30, 2029 1042 days |
7 · Tech stack & innovations
- Chemoenzymatic Cascade Design in High-Potency Multi-Step Custom Organic Synthesis and API Intermediates:
- Coupled ketoreductase and transaminase cascades installing complex chiral centers with absolute stereochemical control (ee >99.8%).
- Computational retrosynthetic route truncation reducing total synthetic step count from 8 chemical stages to 3 biocatalytic operations.
- Microreactor Flow Chemistry & Extraction:
- Hastelloy continuous flow microchannels providing exceptional heat transfer rates (>10,000 W/m²·K) for exothermic biotransformations.
- Multi-stage counter-current centrifugal liquid-liquid extractors achieving complete product recovery with low solvent consumption.
- Continuous SMB Chromatography & Crystallization:
- Industrial simulated moving bed (SMB) chiral column trains resolving optical antipodes with solvent recovery exceeding 95%.
- Automated continuous oscillatory baffled crystallizers (COBC) utilizing inline FBRM probes to enforce metastable zone width control.
Sources 1 · 0 independent · 1 producer sites
Producers' own sites 1
- www.swissbiotech.org producer checked 2026-11-22